Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

European Haematology Association

- PMLiVE

AbbVie reveals new data for presbyopia eye drop treatment

Opthalmic solution is currently being reviewed by the US Food and Drug Administration

- PMLiVE

The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor

Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals how life...

Avalere Health

- PMLiVE

AbbVie, Biogen and Pfizer collaboration creates new resource for genetic exome sequence analysis

Companies have created 'world’s largest' resource for genetic exome sequence analysis

- PMLiVE

Sanofi signs $1bn licence agreement for Eureka’s novel multiple myeloma drug

Multiple myeloma is the second most common blood cancer

- PMLiVE

BMS’s oral AML therapy Onureg receives EU approval

Onureg is the oral version of Vidaza, two of the drugs BMS gained as part of its acquisition of Celgene in 2019

- PMLiVE

BMS and Eisai to collaborate in deal worth up to $3.1bn

The two companies will work on developing a drug for endometrial, ovarian, lung and breast cancers

- PMLiVE

J&J’s Darzalex shows ‘significant’ survival benefit in newly diagnosed multiple myeloma

Darzalex treatment regimen reduced risk of death by 32% after nearly five years follow-up

Roche Basel Switzerland

Roche reveals four-year follow-up data for Venclyxto in CLL at EHA2021

At 30 months post-treatment, 26.9% of Venclyxto-treated patients had undetectable minimal residual disease

- PMLiVE

BMS’ Zeposia gains FDA approval in ulcerative colitis

Treatment was initially approved in 2020 for multiple sclerosis

- PMLiVE

FDA priority review granted for J&J, Legend Biotech’s myeloma CAR T therapy

CAR T therapy demonstrated an overall response rate of 97% in relapsed/refractory multiple myeloma patients after 12.4 months

- PMLiVE

BMS links up with Exscientia for $1.2bn AI drug discovery deal

Deal focuses on the use of AI to discover drug candidates across a number of therapeutic areas

- PMLiVE

BMS builds case for cardiovascular drug mavacamten with new analysis

BMS initially picked up mavacamten as part of its $13.1bn acquisition of MyoKardia last year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links